PMID 11971970
Clinical trials that successfully reduce these abnormal protein deposits have demonstrated only modest disease-modifying effects (6, 7) highlighting the continued need for additional therapeutic approaches to prevent, slow and treat AD
[PubMed] [Google Scholar] 48.Sikiric P., Seiwerth S., Grabarevic Z., Petek M., Rucman R., Turkovic B., Rotkvic I., Jagic V., Duvnjak M., Mise S
Every compound here is research-use-only and not approved by the FDA for human use
Reputable clinics prioritize patient safety, which may reflect in the cost
4 Based on the new information presented here, we would additionally suggest that there is a low threshold to refer patients with clEDS and gastrointestinal complaints to a gastroenterologist